SCHEMBL10242930

SCHEMBL10242930

CCCC(=O)NCc1cccc(-c2ccco2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT6 Q96LA8 1/20 0.60
CYP3A4 P08684 2/20 0.50
CYP2C19 P33261 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
ALDH1A1 P00352 2/20 0.49
HPGD P15428 2/20 0.49
ADORA3 P0DMS8 1/20 0.46
ADORA2A P29274 1/20 0.46
ADORA2B P29275 1/20 0.46
ADORA1 P30542 1/20 0.46
AOC3 Q16853 2/20 0.46
MEN1 O00255 1/20 0.46
POLB P06746 1/20 0.46
KMT2A Q03164 1/20 0.46
KEAP1 Q14145 1/20 0.46
EPHX2 P34913 3/20 0.45
KDM4E B2RXH2 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12303899 0.82 PRMT6 (0.51) PRMT6ALDH1A1HPGDMEN1KMT2A
SCHEMBL10242910 0.82 PRMT6 (0.53) PRMT6L3MBTL1ALDH1A1HPGDADORA3
SCHEMBL10243163 0.81 PRMT6 (0.59) PRMT6CYP3A4CYP2C19ALDH1A1HPGD
SCHEMBL17549817 0.80 CYP3A4 (0.68) CYP3A4CYP2C19L3MBTL1HPGDMEN1
SCHEMBL10242915 0.80 PRMT6 (0.53) PRMT6ALDH1A1HPGDPOLBKMT2A
SCHEMBL10242931 0.79 PRMT6 (0.56) PRMT6CYP3A4CYP2C19L3MBTL1ALDH1A1
SCHEMBL8641716 0.78 EPHX2 (0.69) ALDH1A1HPGDPOLBEPHX2SMN1; SMN2
SCHEMBL1016234 0.78 PRMT6 (0.58) PRMT6ALDH1A1HPGDMEN1POLB
SCHEMBL10242902 0.78 PRMT6 (0.51) PRMT6L3MBTL1ALDH1A1HPGDMEN1
SCHEMBL1317763 0.78 TDP1 (0.59) PRMT6CYP3A4CYP2C19ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 PRMT6 1751/4885CYP3A4 1107/4885CYP2C19 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.